(PharmaNewsWire.Com, September 19, 2017 ) High Potency Active Pharmaceutical Ingredients (HPAPI) are pharmacological intermediates or substances which are active at concentrations below 150 micrograms per kilogram of body weight. They are characterised by high degree of specificity and can bind to specific receptors or enzymes which can cause cancer, reproductive problems and developmental disorders, at low doses. New drugs which are being released into the market have these high potency active pharmaceutical ingredients, leading to high growth of this market.
High Potency Active Pharmaceutical Ingredients have a new range of effective medicines to treat cancer and other hazardous diseases. After the mapping of human genome was done, cancer drugs were made not only for different patients but also for different cancers. However the production of these drugs is difficult, since they are active at very low concentrations. They can pose health problems to workers if they aren’t handled with care. Attentive monitoring has to be done in order to prevent contamination of drugs with foreign substances, requiring specialized equipment for managing air quality and handling HPAPI’s.
The driving factors of Middle East and Africa High Potency Active Pharmaceutical Ingredients market are their low price, rising healthcare prices, growing number of pharmaceutical manufacturers and patients and government initiatives to expand the usage of generic medicines to cut down healthcare costs. The restraints of this market are high price of equipment, stringent regulatory requirements and lack of skilled workers.
The Middle East and Africa High Potency Active Pharmaceutical Ingredients market is segmented on the basis of type into innovative HPAPI’s and generic HPAPI’s. Innovative HPAPI’s has the largest market share due to factors like many number of them being patented, higher price as compared to generics, pharmaceutical manufacturers focusing on production of new drugs and demand for novel anti-cancer medicines. Based on synthesis, the market is divided into biotech HPAPI’s and synthetic HPAPI’s. Synthetic HPAPI’s have a larger market share due to rise of new drugs in the market, ease of production, technological improvements in synthesis and approval for the production of new drugs.
Based on therapeutic application, the market is segmented into oncology, glaucoma, hormonal balance and others. Oncology has the largest share in the market. Factors such as rising incidence of cancer and launch of new target therapies is the reason for rise in the therapeutic segment.
The High Potency Active Pharmaceutical Ingredients market in this region is divided based on geography broadly into Middle East and Africa. The market is still in its emergent stages in the region. Factors such as increasing incidence of cancer, increasing research in cancer cure and approvals for the production of new drugs is going to drive the market in this region.
Some of the major players in the market include Pfizer, Inc. (U.S.), Novartis International AG (Switzerland), Sanofi (France), F. Hoffmann-La Roche Ltd. (Switzerland), Eli Lilly and Company (U.S.), Bristol-Myers Squibb (U.S.), Boehringer Ingelheim (Germany), Teva Pharmaceutical Industries Ltd. (Israel), Merck & Co., Inc. (U.S.), AbbVie Inc. (U.S.), and Mylan Inc. (U.S.).
About Us: Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and sksillset dedicatedly serve clients from various industries and regions.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
